This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Jan;213(1):113.

doi: 10.1097/JU.0000000000004243. Epub 2024 Sep 27.

Editorial Comment

Shane Kronstedt¹, Eric A Singer²

Affiliations

Affiliations

¹ Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
² Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

PMID: 39330871
DOI: 10.1097/JU.0000000000004243

Editorial

Editorial Comment

Shane Kronstedt et al. J Urol. 2025 Jan.

. 2025 Jan;213(1):113.

doi: 10.1097/JU.0000000000004243. Epub 2024 Sep 27.

Authors

Shane Kronstedt¹, Eric A Singer²

Affiliations

¹ Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
² Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

PMID: 39330871
DOI: 10.1097/JU.0000000000004243

No abstract available

PubMed Disclaimer

Comment on

Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.
Shore ND, De Giorgi U, Freedland SJ. Shore ND, et al. J Urol. 2025 Jan;213(1):110-113. doi: 10.1097/JU.0000000000004228. Epub 2024 Sep 3. J Urol. 2025. PMID: 39226589 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources